Guggenheim Capital LLC Has $1.15 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Guggenheim Capital LLC reduced its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 22.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 13,139 shares of the biotechnology company's stock after selling 3,725 shares during the period. Guggenheim Capital LLC's holdings in Blueprint Medicines were worth $1,146,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BPMC. Sanctuary Advisors LLC acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $202,000. Synovus Financial Corp grew its stake in shares of Blueprint Medicines by 4.0% during the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company's stock worth $2,224,000 after purchasing an additional 922 shares during the period. Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock worth $3,259,000 after purchasing an additional 265 shares during the period. Exome Asset Management LLC acquired a new stake in shares of Blueprint Medicines during the third quarter worth $3,395,000. Finally, Empirical Asset Management LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $2,348,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BPMC. Jefferies Financial Group began coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com cut Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. JMP Securities reissued a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Morgan Stanley initiated coverage on Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus target price of $124.53.

Insiders Place Their Bets

In other news, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

BPMC stock traded up $0.85 during midday trading on Monday, reaching $88.51. 786,733 shares of the company were exchanged, compared to its average volume of 770,079. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business has a 50-day moving average price of $87.46 and a two-hundred day moving average price of $93.18. Blueprint Medicines Co. has a one year low of $73.04 and a one year high of $121.90. The firm has a market capitalization of $5.66 billion, a price-to-earnings ratio of -81.95 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.